2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 1,501–1,600 of 2,029
Noo-In, S., Somdee, T., Srichomphoo, C., Ruetrakul, J., Namyota, C., Nghiep, L. K., & Khiewkhern, S. (2026) · Journal of Health Research · doi:10.56808/2586-940x.1182
Morar-Stan, A., Dobrotă, L., Radutu, A., & Domnariu, C. D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031112
“…form of diabetes in the pediatric population, is a chronic autoimmune condition that leads to the progressive destruction of pancreatic β -cells, resulting in an absolute endogenous insulin deficiency and high blood sugar (hyperglycemia) and requiring lifelong insulin therapy for survival [1,2].”
Definition, diagnosis and classification of diabetes mellitus
Ékoé, J.-M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00342-3
Xu, L., Wang, S., Wang, Q., Bai, X., Zhao, M., Huang, Y., Wang, X., Wang, Z., Yin, J., & Wan, M. (2026) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2026.109663
Liu, J., Lin, S.-H., & Li, Y. (2026) · Medicine · doi:10.1097/md.0000000000047380
“[19] Hypertension was defined as self-reported hypertension, use of antihypertensive medication, or average systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 80 mm Hg, according to the 2017 American College of Cardiology/American Heart Association hypertension guidelines.”
Guerrero-Flores, M. H., Maeda-Gutiérrez, V., el Cruz, M., et al. (2025) · IEEE International Autumn Meeting on Power, Electronics and Computing (ROPEC) · doi:10.1109/ropec68163.2025.11354062
“Diagnosis typically relies on glycemic biomarkers such as fasting plasma glucose, glycosylated hemoglobin (HbA1C), oral glucose tolerance testing (OGTT), and the homeostasis model assessment of insulin resistance (HOMA-IR) [8].”
Selim, S., Rahman, M. H., Mustari, M., Mohiuddin, S. M., Ahammed, A., Hannan, M. A., Sharifuzzaman, M., Mahjabeen, S., Saifuddin, M., Rahman, M. M., et al. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s576436
Laysandro, R., Harijanto, E. A., & Sie, N. A. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1737431 · Cited by 1
Jiang, Y., Chen, D. C., Huang, J., Chang, H., Zhang, H., Cai, Y., Fang, H., Han, Y., & Peng, X. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1708190
Wang, C., Lin, K., Zhang, H. Z., Liu, T., Zeng, Z., Luo, W., Jiang, Y., Zhang, X., & Du, S. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01088-2
“Hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) are essential tools for diagnosing diabetes and pre-diabetes [1], but HbA1c’s accuracy as a diagnostic standard is not infallible.”
Astiarraga, B., Rodríguez-Castellano, A., Ceperuelo‐Mallafré, V., Marsal-Beltran, A., Osuna‐Prieto, F. J., Vilanova, N., Gracia-Sancho, J., Quer, J. C., Ana, M., Balteiro, A. P., et al. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01141-x
“T2D diagnosis was based on a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L, an HbA 1c level ≥ 48 mmol/mol, or a previous clinical diagnosis [23].”
InfluentialZiyadullaev, S., Eshmuradova, S., Kadirov, J., Saidov, M., Ruzimurodov, N., & Nazirkulov, O. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02187-0 · Cited by 1
“Diagnostic criteria included FPG ≥ 7.0 mmol/L, 2-hour OGTT ≥ 11.1 mmol/L, glycated haemoglobin (HbA1c) ≥ 6.5%, or random plasma glucose ≥ 11.1 mmol/L in the presence of classic symptoms (polydipsia, polyuria, and weight loss) [16].”
InfluentialGuo, J., Li, Z., Patel, S. A., CHANG, H. H., Ali, M. S., & Varghese, J. S. (2026) · Diabetes Care · doi:10.2337/dc25-2069
Sarıkaya, U., Selek, Ş., & Sarıkaya, A. (2026) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2026.111097
Rangare, V., Nagwanshi, J., & Raghuwanshi, K. D. (2026) · Cureus · doi:10.7759/cureus.103178
“International guidelines like the American Diabetes Association Standards of Care 2024 [11] and the National Institute for Health and Care Excellence (NICE) 2024 guidelines [22], as well as recent narrative and systematic reviews, highlight the significance of routine vitamin B12 screening among…”
Current Concepts in Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State
Ruiz-Barrera, M. A., Rojas, G., Santamaría, A., Maldonado, A. F. R., Bernate, F., Mariottiz, S., Chong, C. S., Salazar, M. R., & Castellanos, D. S. G. (2026) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2026.161002
A region-wide hub and spoke approach to standardize and decentralize type 1 diabetes management
Minuto, N., Spacco, G., Siri, G., Leoni, M., Gaiero, A., Corona, M. F., Minghetti, D., Ramenghi, L. A., Pintabona, A., Calevo, M. G., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1763175
“Moreover, these improvements were not limited to changes in mean CGM values but also translated into a higher proportion of patients achieving international recommended glycaemic targets (8).”
Boscart, T., Barras, A., Plaisance, V., Pawlowski, V., Giovanelli, E., Bardor, M., d’Hulst, C., & Abderrahmani, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020223
“Aside from gestational diabetes (GD) and less common forms such as iatrogenic diabetes, exocrine pancreas-related diabetes (e.g., cystic fibrosis), and virus-induced diabetes, type 1 (T1D) and type 2 diabetes (T2D) account for over 90% of all diagnosed cases [5].”
Yilmaz, O., Erinç, O., Yoldemir, Ş. A., & Akarsu, M. (2026) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.1809214
Tian, G., Qian, C., Liu, Z. K., Xu, Y., Yang, L., & He, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1733377 · Cited by 1
Pillutla, S., Narendiran, V., Basapur, R., Sahoo, J., & Sagili, H. (2026) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-026-02353-3
Liu, D., Xie, H., Chen, H., Jiang, M., Liu, D., Shu, T., Yuan, Z. Y., Fan, X., & Wang, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1766153
Association of insulin and GH/IGF-1 derangements and heart failure: a narrative review
Cesaro, A., Calabrò, P., Ruvolo, A., & Fazio, S. (2026) · Exploration of Cardiology · doi:10.37349/ec.2026.101294
Sänger, K., Reyes, C. R. T., Cahyadi, O., Ebigbo, A., Schmidt, W. E., & Quast, D. R. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1780005
Wu, Z., Qiu, C., Pan, M., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05600-7
“Type 2 diabetes mellitus (T2DM) was diagnosed based on the American Diabetes Association criteria as fasting blood glucose (FBG) ≥ 7.0 mmol/L, glycated hemoglobin (HbA1c) ≥ 6.5%, self-reported physician diagnosis, or use of glucose-lowering medication [21].”
InfluentialYücel, M., ÇOMAKLI, H., Sağlam, M. F., Erdoğan, K. E., Elipek, N. G., Yavuz, O. A., & Uğuz, E. (2026) · Diagnostics · doi:10.3390/diagnostics16040560
“…423 consecutive patients with a diagnosis of type 1 or type 2 DM for at least 1 year according to the American Diabetes Association (ADA) criteria [16] and ≥ 50% stenosis or occlusion in at least one infrapopliteal and/or pedal artery in the index extremity detected by BTA, MRA, and/or DSA were…”
Diabetes and Pancreatic Cystic Neoplasms—Dangerous Liaisons
Crippa, S., & Piemonti, L. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.56869
Zhao, Y., Wang, W., Wang, Z., Ma, J., Zhang, J., Shao, J., Zhou, K. S., Pan, Q., Nie, Z., Xu, G., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07867-y · Cited by 1
“In the Chinese Physical Examination Cohort, diabetes was defined as fasting blood glucose (FBG) ≥ 7.0 mmol/L or HbA1c ≥ 6.5% [24].”
InfluentialYu, C., Zhang, X., Wang, R., Zhang, C., Gao, Y., Yixin, W. A. N. G., Lv, L., Wang, Z., & Zhang, H. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157975 · Cited by 1
DiLiberto, F. E., Kamath, H. E. R., Olson, M. L., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113162
Thomas, R., Ambookan, P. V., Abdurahman, A. P., John, M., Thampi, R., & Rubens, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100687
Godfrey, H., Ribeiro, É. D. M., Verton-Shaw, S., Shoveller, A. K. K., Kostiuk, D., Kelly, J., Blades, J. S., Johnson, R., & Verbrugghe, A. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalag013 · Cited by 1
“2,4 Similarly, in cats there is particular interest in the high-carbohydrate content (referring to nitrogen-free extract [NFE]) of commerciallyavailableca tfoodscomparedwiththatofthetypical prey species 16–19 as the driver for the positive association of feed-ingextrudeddryfoodwithobesityonsetandIR.”
Jia, H., Liu, S., zhou, M., Cao, Y., Gan, X., He, P., Li, F., Xu, Y., Wang, B., & Xu, X. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-08732-y
“…by the International Association of Diabetes and Pregnancy Study Groups (IADPSG), GDM is diagnosed if any of the following thresholds are met: Fasting glucose (0 h) ≥ 92 mg/dL (5.1 mmol/L), 1-hour glucose (1 h) ≥ 180 mg/dL (10.0 mmol/L) and 2-hour glucose (2 h) ≥ 153 mg/dL (8.5 mmol/L) [15, 16].”
InfluentialPoudel, D. K., Khadayat, K., Ghimire, S., Satyal, P., & Setzer, W. N. (2026) · Journal of Chemistry · doi:10.1155/joch/1181388
Fry, H. T., Gluck, M. E., de Baca, T. C., Stinson, E. J., Ünlü, Y., Piaggi, P., Krakoff, J., & Chang, D. C. (2026) · Obesity · doi:10.1002/oby.70148
Li, X., Liu, Y.-D., Yang, C., Zhang, P., Gong, Y.-M., Rui-sheng, D., & Liu, Y. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1776271
Cao, R., Xu, B., Wang, Y. L., Lu, X., Qin, X., Cheng, X., Sun, G., Yang, J., Sun, N., Sun, G., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1726451
Wu, Y., Li, M., Li, H., Li, H., Shen, T., Liu, Y., Wang, G., Sun, H., Li, Z., & Zhang, G. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1674886
Karaban, K., Żywiec, W., & Dorota, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4986
Dur, R., Baş, A., & Dur, G. (2026) · Biological Trace Element Research · doi:10.1007/s12011-026-05033-5
“Its prevalence continues to increase globally, paralleling the rise in obesity and maternal age [ 2, 3].”
YEŞİLDAL, M., Tetik, A., & Siyar, A. (2026) · Patient Preference and Adherence · doi:10.2147/ppa.s586362
To Determine Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy
Bhadade, R. R., Dongare, N., Harde, M., deSouza, R., & Patel, A. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1371
Liang, J., Yang, R., Liang, Y., Fan, X., Cai, M., Li, S., Chen, L., Wu, G., Wang, X., Huang, J., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113187
Darbandi, M. H., & Dalmacio, L. M. M. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.16199
“Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is characterized by chronic hyperglycemia driven by insulin resistance and progressive beta cell dysfunction (American Diabetes Association Professional Practice Committee, 2024; Galicia Garcia et al., 2020).”
Prevalence and clinical correlates of pre-operative glucose homeostasis in patients with acromegaly
Chiang, P.-W., & Chen, H.-S. (2026) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2026.101686
Li, S., Hua, B., Zhu, P., Hu, S., Kreher, D., Schmalz, G., & Xiao, H. (2026) · Head & Face Medicine · doi:10.1186/s13005-026-00597-y
“Diabetes mellitus was identified following the American Diabetes Association diagnostic criteria [23].”
Heriyani, D. Y., Purnomo, A. S., & Irawan, B. (2025) · International Conference on Information System & Information Technology (ICISIT) · doi:10.1109/icisit66233.2025.11402980 · Cited by 1
“The global prevalence of DM continues to rise, particularly in developing countries, creating significant healthcare challenges and economic burdens [2].”
de Sá, D. S. D. S., & da Trindade, R. A. (2026) · Jornal Brasileiro de Ginecologia · doi:10.5327/jbg-2965-3711-122
Wu, Z., He, S., Zhu, F., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1764209
Nemitz, N., Elias, M., & König, M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030287 · Cited by 1
Racial/ethnic and sex disparities in mortality among US cancer survivors
Xiong, Q., Luo, Y., Han, K., Pan, Y., Wang, J., He, J., Li, J., Xu, W., Xiang, T., Su, S., et al. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06429-5
“Participants were considered to have diabetes if they met any of the following criteria: a fasting glucose level equal to or greater than 7 mmol/L (≥ 126 mg/dL), a hemoglobin A1c level equal to or greater than 6.5%, or a prior diagnosis of diabetes (ElSayed et al. 2024).”
InfluentialBriones-Claudett, K. H., Benites-Solis, J., Cedeño, P. D., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1762878
Zhang, J., Gao, W., Hu, S., & Liu, Y. (2025) · Advances in World Medical Research · doi:10.71204/83zf0y22
Guo, Y., Zhang, X., Yang, A., Guo, Y., Dong, S., Wang, L., Zhang, N., & Zhou, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1783428
Point prevalence of motor neuropathy in children and adolescents with type 1 diabetes mellitus
Lopes, J. H. B., Fonseca, J., Silveira, F. B. C., & Castro-Correia, C. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01865-z
Ling, Y., Chen, Y., Yu, X., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1733119
“The diagnosis of T2DM was based on the ADA diabetes guidelines (19).”
Gupta, H., Singh, R., Singh, K., Gupta, M., Kaur, J., Singla, M., & Garg, S. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_842_25
Prevalence and Risk Factors of Diabetes and Prediabetes: A Population-Based Survey
Hussein, N. R., Mohammed, W. A. E. S., Musa, D. H., Abozait, H. J., Naqid, I. A., Majed, H. S., Aldoski, Z. S. A., Haji, R. S., Mohammed, H. H., Hito, L. S., et al. (2026) · Galician Medical Journal · doi:10.21802/e-gmj2026-a05
Göbl, C. S., Piersanti, A., Heinzl, F., Linder, T., Morettini, M., & Tura, A. (2026) · Diabetology · doi:10.3390/diabetology7030048 · Cited by 1
Íñiguez-Gutiérrez, L., Díaz-Villavicencio, B., Íñiguez-Mosqueda, O., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01903-w
“Diabetes is broadly classified into two major types: type 1 diabetes (T1D), which is primarily autoimmune and leads to absolute insulin deficiency, and type 2 diabetes (T2D), which is character - ized by insulin resistance and relative insulin deficiency [2 ].”
Utaisang, A., Pilayon, B., Thanyawarathorn, T., Panomsak, S., & Phoosuwan, N. (2026) · BMC Public Health · doi:10.1186/s12889-026-26828-0 · Cited by 3
Xin, Z., Wang, L., Wu, K., Li, X., Guo, L., Wang, W., Liu, J., Jiang, B., Kang, C., Li, Q., et al. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s569145
“21 ; heart disease, eg, heart failure or myocardial infarction (self-report, physician diagnosis, or related medication); and stroke (self-report, physician diagnosis, medical history, or neurological exam evidence).”
Um, K., Kim, B. J., & Ying, G.-S. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-110831
Brambila‐Tapia, A. J. L., Ponce-Guarneros, J. M., Saldaña-Cruz, A. M., Santos, S. R.-D. L., & Jacobo-Cuevas, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052408
“…(illness count) when they had not been reported by the participant: (a) dyslipidemia, defined as total cholesterol > 200 mg/dL and/or triglycerides > 150 mg/dL [40]; (b) diabetes, defined as fasting glucose > 126 mg/dL [41]; and (c) hypertension, defined as systolic blood pressure > 140 mmHg [42].”
Non-albumin proteinuria is associated with all-cause mortality in community-dwelling adults
Kabasawa, K., Hosojima, M., Ito, Y., Kabasawa, H., Tanaka, J., Iino, N., Tsugane, S., Nakamura, K., Saito, A., & Yamamoto, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-39833-5
“14 or use of antidiabetic medication.”
Arethiya, N., Krammer, L., David, J. A., Bakshi, V., Basuchoudhary, A., Bhuiyan, U., Sen, S., Mazumder, R., & McNeely, P. M. (2026) · medRxiv · doi:10.64898/2026.03.04.26347604
Nibbaragandla, R. S., Nelluri, P. S., Thiriveedhi, S., Narra, C., Palagani, A. S., Ginjupalli, A., & Chowdary, C. H. (2026) · Cureus · doi:10.7759/cureus.104756
“Group A was defined by a documented history of T2DM according to the American Diabetes Association (ADA) guidelines, requiring a glycated hemoglobin (HbA1c) level ≥6.5% or the active use of glucose-lowering therapy [17].”
InfluentialInsulin Resistance: Pathophysiology, Molecular Mechanisms, and Genetic Insights
Häring, H., & Gallwitz, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00002-1
Han, Y., Xiong, Q., Wang, J., Wang, A., Chen, Q., Liu, Y., & Cheng, K. (2026) · Metabolomics · doi:10.1007/s11306-026-02409-5
Kong, L., Shen, L., Xie, L., Li, Z., Zhu, C., Zhang, S., Huang, Y., Wang, Z., & Chen, H. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-08908-6
“The American Diabetes Association (ADA) recommends screening before 15 weeks using FPG or HbA1c to identify overt diabetes [17].”
Khan, F. A., Tabassum, R., Siddiqui, M. N. A., Haque, M. A., Hasan, M. A., Alam, M. M., Islam, M. M.-U., & Khan, M. S. R. (2026) · TAJ Journal of Teachers Association · doi:10.70818/taj.v39i01.0605
Dong, S., Jiang, J., Yang, S., & Hua, Q. (2026) · Frontiers in Surgery · doi:10.3389/fsurg.2026.1742244
“Recurrence was recorded only after complete wound healing and was confirmed by two independent assessors based on follow-up records or wound photographs (20).”
Nakamura, S., Inoue, R., & Narimatsu, H. (2026) · PNAS Nexus · doi:10.1093/pnasnexus/pgag062 · Cited by 2
“Current guidelines recommend reevaluating glucose tolerance at 3-year intervals in individuals with normal screening results (1).”
InfluentialGlucose metabolism disorders and changes in cardiovascular risk among adult Peruvian population
Sedano-Espinoza, J., Perez-Ochoa, K., Yalico-Quispe, E., & Bernabé‐Ortiz, A. (2026) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22701.3
“…was the exposure of interest, evaluated only at the cohort ’ s baseline, and defined according to results of the oral glucose tolerance test, 21 split into three groups: normoglycaemia (preprandial [fasting] glucose <100 mg/dl and postprandial glucose <140 mg/dl); prediabetes (preprandial…”
Gładych-Macioszek, A., Mantaj, U., Toboła-Wróbel, K., Radzicka, S., Sibiak, R., Adamczak, Ł., Desoyé, G., & Wender-Ożegowska, E. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-08927-3
“This trend has significant clinical implications, as hyperglycemia during pregnancy is associated with a range of adverse maternal, perinatal, and neonatal outcomes [3, 4].”
InfluentialTirzepatide and semaglutide: different twins?
Cesaro, A., Acerbo, V., & Calabrò, P. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag028
“9,10 In this context, the therapeutic priority is not merely glycaemic control but cardiovascular prevention, and the choice of GLP-1RA is guided by an organ-protective strategy rather than glucose-lowering alone.”
He, Y., Liu, M., Xing, B., Xu, H., He, J., Mai, W., Qin, S., Luo, Z., Wang, X., Xu, Y., et al. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/5522115
Lara-Castro, J. M., Martínez-Aguirre, A. R., Castro-Rosales, J. G., et al. (2026) · doi:10.35366/121744
Zeng, Y., Li, P.-Y., Zhi, C. H. E. N., Yao, N.-F., Ye, H., Gui, Z.-H., Chen, H.-L., Liu, L., Wan, H., & Shen, J. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i3.115304
Sakhanberidze, N., Namoradze, M., Charkviani, N., Mantskava, M., Момцелидзе, Н., Delibashvili, D., & Gamkrelidze, N. (2026) · Open Medicine · doi:10.1515/med-2026-1403
“Diabetes mellitus is a complex metabolic disorder characterized by persistent hyperglycemia resulting from absolute insulin de fi ciency and/or impaired insulin action, which disrupts normal glucose utilization [1].”
Cuculić, M. T., Sergo, D., Kavazović, I., Peršić, V., Wensveen, F. M., & Wensveen, T. T. (2026) · Research Square · doi:10.21203/rs.3.rs-9020037/v1
Enhanced Diabetes Management with Digital Twins: A Scoping Review (Preprint)Preprint
Cinar, B., van den Boom, L., & Maleshkova, M. (2026) · doi:10.2196/preprints.91729
Chen, S., & Lu, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1739521 · Cited by 1
“Although advances in precision endocrinology have motivated more nuanced taxonomies, contemporary classi fi cation systems remain largely structured around obesity-associated insulin resistance (IR) and autoimmune-mediated b -cell destruction (2).”
InfluentialElkind-Hirsch, K. E., Armatta, M., VEILLON, E. W., Jr., Schiavon, S., & Cappon, G. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-08944-2
Gómez-Torres, P., Blázquez-Ornat, I. R., del Hoyo, M. L. L., de Corcuera, M. E. S.-D., López, E. F., Arbués, E. R., Perez-Calahorra, S., Gómez-Barrera, M., & Fernández‐Rodrigo, M. T. (2026) · Health Economics Review · doi:10.1186/s13561-026-00755-7
“Management combines lifestyle modification (nutrition, physical activity, weight control) with stepwise pharmacotherapy [1, 43].”
Labile hemoglobin A 1c : an additional tool for identifying patients with poor glycemic control
Han, W., Meng, Y., Guo, X., et al. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-0291
“To the Editor, Glycated hemoglobin (HbA 1c ) is the cornerstone for diagnosing and monitoring type 2 diabetes mellitus (T2DM), re fl ecting average glycemia over 2 – 3 months [1].”
Sun, W., Chen, S., Shu, H., Gu, Y., Yang, Y., Xu, Y., Zhang, C., Zhao, H., Yang, Z., & Zhang, Y. (2026) · Glycobiology · doi:10.1093/glycob/cwag020
Jao, J. K., Mukonda, E. E., Madlala, H. P., Myer, L., Zerbe, A., Legbedze, J., Rusch, J. A., Matyesini, S., Josefson, J. L., McComsey, G., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag111
Shin, S., Woo, H., Lee, H.-Y., Lee, Y., Kim, H., Lee, Y.-A., Shin, C., Lee, H.-Y., & Kim, J. (2026) · Journal of Korean medical science · doi:10.3346/jkms.2026.41.e118
Kalyva, S., Argyropoulou, D., Koulouvaris, P., Tsolakis, C. K., Terzis, G. D., Nomikos, T., Geladas, N. D., Theodorou, A. A., & Paschalis, V. (2026) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk11010125
“Fat intake was controlled by prescribing both the type and exact amount of fat, distributing it across meals, and ensuring the total daily energy intake matched the individualized target [1].”
InfluentialAngulo-Ramírez, L. A., Goñi, J. W. G., & Bernabé‐Ortiz, A. (2025) · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo · doi:10.35434/rcmhnaaa.2025.182.2796
Shayan, S. J., Siddiqi, N., Carswell, C., Rehman, K., Fahim, O., Walker, S., Samad, Z. Z., Muhammadi, A. F., & Zavala, G. A. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1705887
“Fasting blood glucose levels classified by the American Diabetes Association as optimal 100, prediabetes ≥ 100 to 126, diabetes ≥ 126 mg/dL (31).”
Wakode, S. L., Gour, R., Lokhande, S. L., Singhai, A., Wakode, A., Bharshankar, R. N., Singh, J., & Sukumar, M. (2026) · Cureus · doi:10.7759/cureus.105493
“…B₁₂ deficiency as a common adverse effect of metformin and advises testing vitamin B₁₂ levels in patients with suggestive symptoms, as well as considering periodic monitoring in individuals with risk factors such as prolonged therapy, higher doses, or pre-existing nutritional deficiencies [22].”
Zhang, F., Wu, R., Cheng, Z., Zhang, N., Che, Y., Chen, B., Huo, X., Liang, P., Chen, Y., Wang, Q., et al. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01944-w · Cited by 2
“Type 2 diabetes mellitus (T2DM) is a complex chronic metabolic disease primarily characterized by insulin resistance or insufficient secretion, leading to elevated blood glucose levels and lipid metabolism abnormalities [1].”
InfluentialRajan, K., Jutley, A., Holliday, M. W., & Navaneethan, S. D. (2026) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s522424
Silver, D., Vasileiadi, M., Menon, T., Pople, C. B., Musa, L., Rabin, J. S., Giacobbe, P., Hamani, C., Davidson, B., Lipsman, N., et al. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07999-x
“Participants were classified as American Diabetic Association (ADA)-normal glycemic group (HbA1c levels 5.7% and/or FG levels 5.6 mmol/L) or ADA-elevated (HbA1c levels ≥ 5.7% and/or FG ≥ 5.6 mmol/L) [27].”
InfluentialCherniaieva, А. О., Mykytyuk, M., & Karachentsev, Y. I. (2026) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2026.1.05
Taştemur, Ş., Karataş, T. D., Aldemir, Ö., & Öz, M. (2026) · Konuralp Tıp Dergisi · doi:10.18521/ktd.1850416
Sembiring, S. B., Rusip, G., Girsang, E., & Pardianto, G. (2026) · Clinical ophthalmology · doi:10.2147/opth.s593182
Wen, X., Chen, L., Mo, Y., Guo, H., Pei, R., Lyu, Y., Luo, H., & Jun, W. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s579326
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.